Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLoans and Notes ReceivablesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Gyre Therapeutics (GYRE) Long-Term Debt Repayments (2016 - 2018)

Gyre Therapeutics has reported Long-Term Debt Repayments over the past 9 years, most recently at $5.1 million for Q1 2018.

  • Quarterly Long-Term Debt Repayments fell 24.73% to $5.1 million in Q1 2018 from the year-ago period, while the trailing twelve-month figure was $5.1 million through Dec 2018, down 64.51% year-over-year, with the annual reading at $5.1 million for FY2018, 64.51% down from the prior year.
  • Long-Term Debt Repayments was $5.1 million for Q1 2018 at Gyre Therapeutics, up from $403000.0 in the prior quarter.
  • Over five years, Long-Term Debt Repayments peaked at $10.3 million in Q4 2016 and troughed at $218000.0 in Q1 2014.
  • The 5-year median for Long-Term Debt Repayments is $634000.0 (2016), against an average of $2.6 million.
  • Year-over-year, Long-Term Debt Repayments surged 1089.46% in 2016 and then tumbled 96.07% in 2017.
  • A 5-year view of Long-Term Debt Repayments shows it stood at $478000.0 in 2014, then skyrocketed by 80.54% to $863000.0 in 2015, then surged by 1089.46% to $10.3 million in 2016, then tumbled by 96.07% to $403000.0 in 2017, then surged by 1161.04% to $5.1 million in 2018.
  • Per Business Quant, the three most recent readings for GYRE's Long-Term Debt Repayments are $5.1 million (Q1 2018), $403000.0 (Q4 2017), and $282000.0 (Q3 2017).